[go: up one dir, main page]

MX2014008441A - Enzimas de clostridium histolyticum y metodos para el uso de los mismos. - Google Patents

Enzimas de clostridium histolyticum y metodos para el uso de los mismos.

Info

Publication number
MX2014008441A
MX2014008441A MX2014008441A MX2014008441A MX2014008441A MX 2014008441 A MX2014008441 A MX 2014008441A MX 2014008441 A MX2014008441 A MX 2014008441A MX 2014008441 A MX2014008441 A MX 2014008441A MX 2014008441 A MX2014008441 A MX 2014008441A
Authority
MX
Mexico
Prior art keywords
methods
collagenase
enzymes
clostridium histolyticum
detecting
Prior art date
Application number
MX2014008441A
Other languages
English (en)
Other versions
MX351448B (es
Inventor
Wayne K Herber
Original Assignee
Auxilium Int Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auxilium Int Holdings Inc filed Critical Auxilium Int Holdings Inc
Publication of MX2014008441A publication Critical patent/MX2014008441A/es
Publication of MX351448B publication Critical patent/MX351448B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24003—Microbial collagenase (3.4.24.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24027—Thermolysin (3.4.24.27)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
    • G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
    • G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
    • G01N2333/96419—Metalloendopeptidases (3.4.24)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)

Abstract

La invención se refiere a un ácido nucleico recombinante y polipéptidos que codifican la colagenasa I y colagenasa II, métodos para la reparación de las mismas y métodos para el uso de las mismas. La presente invención también proporciona un método para detectar la secreción de una toxina hemolítica por una cepa de producción bacteriana, en donde la cepa de producción produce una colagenasa, previo a la administración terapéutica de dicha colágenasa a un paciente y métodos para detectar la presencia de una toxina hemolítica en una composición de colagenasa.
MX2014008441A 2012-01-12 2013-01-10 Enzimas de clostridium histolyticum y métodos para el uso de los mismos. MX351448B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261585909P 2012-01-12 2012-01-12
PCT/US2013/020940 WO2013106510A2 (en) 2012-01-12 2013-01-10 Clostridium histolyticum enzymes and methods for the use thereof

Publications (2)

Publication Number Publication Date
MX2014008441A true MX2014008441A (es) 2015-03-13
MX351448B MX351448B (es) 2017-10-16

Family

ID=48782075

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017013257A MX387336B (es) 2012-01-12 2013-01-10 Enzimas de clostridium histolyticum y metodos para el uso de los mismos.
MX2014008441A MX351448B (es) 2012-01-12 2013-01-10 Enzimas de clostridium histolyticum y métodos para el uso de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017013257A MX387336B (es) 2012-01-12 2013-01-10 Enzimas de clostridium histolyticum y metodos para el uso de los mismos.

Country Status (13)

Country Link
US (8) US9757435B2 (es)
EP (4) EP4276180A3 (es)
JP (5) JP6263755B2 (es)
AU (6) AU2013208028B2 (es)
BR (1) BR112014017229B1 (es)
CA (2) CA2861033C (es)
DK (2) DK2802652T3 (es)
ES (3) ES2740499T3 (es)
HU (2) HUE046160T2 (es)
MX (2) MX387336B (es)
NZ (6) NZ797997A (es)
PT (2) PT3584317T (es)
WO (1) WO2013106510A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2790717T3 (da) * 2011-12-14 2018-07-30 Univ Arkansas Afgivelse af terapeutiske midler ved hjælp af et kollagenbindende protein
AU2013208028B2 (en) 2012-01-12 2016-04-28 Auxilium International Holdings, Inc. Clostridium histolyticum enzymes and methods for the use thereof
RU2540919C1 (ru) * 2013-09-27 2015-02-10 Государственное автономное учреждение здравоохранения "Республиканская клиническая больница Министерства здравоохранения Республики Татарстан" Способ безоперационного лечения контрактуры дюпюитрена iii-iv степени тяжести
PT107276B (pt) * 2013-11-07 2018-06-07 Univ Aveiro Método para produção de colagenase recombinante para digestão de colagénios
WO2017074257A1 (en) * 2015-10-26 2017-05-04 Nanyang Technological University Non-viable derivatives of clostridium sporogenes as anti-cancer therapeutic agents
WO2018104540A1 (en) * 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
CN110582304A (zh) * 2016-12-08 2019-12-17 库尔维科公司 用于治疗或预防肝脏疾病的rna
US11624060B2 (en) 2017-02-10 2023-04-11 The Board Of Trustees Of The University Of Arkansas Collagen-binding agent compositions and methods of using the same
CN115969318A (zh) 2017-03-01 2023-04-18 恩多风投有限公司 用于评估和治疗橘皮组织的装置和方法
EP3601556A2 (en) 2017-03-28 2020-02-05 Endo Ventures Limited Improved method of producing collagenase
CZ308157B6 (cs) 2017-09-13 2020-01-29 MB PHARMA s.r.o. Kmen bakterie Clostridium histolyticum, kolagenáza připravená s použitím tohoto kmene a její použití
WO2020021330A2 (en) 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
WO2020021332A2 (en) 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
MX2021003154A (es) 2018-09-18 2021-06-23 Endo Global Aesthetics Ltd Composiciones y métodos para tratar celulitis.
CN109355222B (zh) * 2018-11-06 2020-06-02 上海交通大学 对水稻白叶枯病菌具有拮抗作用的芽孢杆菌及分离与应用
KR20210113271A (ko) 2019-01-06 2021-09-15 엔도 글로벌 에스테틱스 리미티드 콜라게나제 제형 및 이의 제조 방법
US12403179B2 (en) 2021-02-18 2025-09-02 The Board Of Trustees Of The University Of Arkansas Release of growth factors at wound healing stages
CN112941058B (zh) * 2021-04-02 2023-12-05 重庆科润生物医药研发有限公司 一种重组溶组织梭菌ii型胶原酶及其制备方法和应用
CN113025599B (zh) * 2021-04-02 2023-09-12 重庆科润生物医药研发有限公司 一种重组溶组织梭菌i型胶原酶及其制备方法和应用
EP4448752A4 (en) * 2021-12-14 2025-06-18 Ramot at Tel-Aviv University Ltd. Modified recombinant collagenase, compositions comprising the same and uses thereof in dental related procedures
CN116286753A (zh) * 2023-01-06 2023-06-23 广州达安基因股份有限公司 重组i型胶原蛋白酶及其突变体的制备方法和应用

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3821364A (en) * 1966-07-08 1974-06-28 Advance Biofactures Corp Process of producing collagenase
JPS5662229A (en) 1979-10-25 1981-05-28 Asahi Glass Co Ltd Electro-optical dimming panel
US4338300A (en) 1981-02-05 1982-07-06 The Regents Of The University Of California Use of purified clostridial collangenase in the treatment of Peyronie's disease
DE3473827D1 (en) 1983-01-05 1988-10-13 Pasteur Institut Highly active collagenolytic preparation and pharmaceutical compositions containing it
US4524065A (en) 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US4645668A (en) 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US4542065A (en) 1984-05-21 1985-09-17 Ppg Industries, Inc. Chemically treated glass fibers and strands and dispersed products thereof
JPS61289885A (ja) 1985-06-14 1986-12-19 Nitta Zerachin Kk コラゲナ−ゼおよびコラゲナ−ゼの製造方法
JP2898022B2 (ja) 1989-09-05 1999-05-31 株式会社ニッピ コラーゲン分解酵素の製造方法
US5252461A (en) 1990-05-01 1993-10-12 The Regents Of The Univ. Of California Mixed immunoglobulins for detection of rheumatoid factors
CA2047306A1 (en) 1990-07-23 1992-01-24 Milan Holjevac Mutant bacterium clostridium histolyticum, a process for the obtaining thereof, and its use in the production of clostripain-free collagenase
US5393792A (en) 1991-11-20 1995-02-28 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase
US5462739A (en) 1991-11-21 1995-10-31 Yeda Research And Development Co., Ltd. Microdelivery device and method for enhanced drug administration to the eye
US5256140A (en) 1992-03-27 1993-10-26 Fallien Cosmeceuticals, Ltd. Composition for levelling skin
WO1994000580A1 (en) 1992-06-22 1994-01-06 Trigen, Inc. Molecular cloning of the genes reponsible for collagenase production from clostridium histolyticum
DK0677110T4 (da) 1992-12-30 2010-05-25 Bioneer As Rekombinant mælkesyrebakterie, der indeholder en inserteret promotor
JP3186881B2 (ja) 1993-02-18 2001-07-11 倉敷紡績株式会社 肝細胞の分離方法
US5332503A (en) 1993-04-16 1994-07-26 Baxter International Inc. Process for purifying collagenase
US5514340A (en) 1994-01-24 1996-05-07 Magnetix Biotechnology, Inc. Device for separating magnetically labelled cells
JP3028852B2 (ja) 1994-06-24 2000-04-04 ロシュ ダイアグノスティックス コーポレーション ヒストリチクス菌から得られるコラゲナーゼおよび２つの他のプロテアーゼの精製混合物
US5589171A (en) 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
CA2158822C (en) 1994-09-27 2008-12-23 Kusuki Nishioka Therapeutic agent for rheumatic disease
US6958150B2 (en) 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
CZ280397A3 (cs) 1995-03-16 1998-04-15 Knoll Aktiengesellschaft Nové, definované směsi enzymů pro získávání buněk a pro léčbu poranění
US5705170A (en) 1995-10-24 1998-01-06 Plantech International, Inc. Herbal cellulite treatments
US5989888A (en) 1996-01-24 1999-11-23 Roche Diagnostics Corporation Purified mixture of collagenase I, collagenase II and two other proteases
PT925364E (pt) 1996-09-06 2003-03-31 Bioteknologisk Inst Sistema de expressao regulavel de bacterias de acido lactico
AU5222498A (en) * 1996-11-19 1998-06-10 Boehringer Mannheim Gmbh Type i recombinant clostridium histolyticum collagenase and its use for isolating cells and cell aggregates
US5830741A (en) 1996-12-06 1998-11-03 Boehringer Mannheim Corporation Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease
US5753785A (en) 1996-12-16 1998-05-19 Fina Technology, Inc. Production of E-B copolymers with a single metallocene catalyst and a single monomer
US6086872A (en) 1997-03-27 2000-07-11 Advance Biofactures Of Curacao, Nv Amelioration of dupuytren's disease
JPH10262658A (ja) 1997-03-28 1998-10-06 Kikkoman Corp ザルコシン・オキシダーゼの結晶、その製造方法及び三次元構造
WO1999017738A1 (en) 1997-10-03 1999-04-15 Lavipharm Laboratories, Inc. A prolamine-plant polar lipid composition, its method of preparation and applications thereof
GB9724802D0 (en) 1997-11-24 1998-01-21 Unilever Plc Antiperspirant or deodorant compoistions
US20020036328A1 (en) 1998-11-16 2002-03-28 William R. Richards, Jr. Offset drain fermi-threshold field effect transistors
FR2788682B1 (fr) 1999-01-26 2001-04-06 Seb Sa Dispositif de thermographie
US6022539A (en) 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
RU2180002C2 (ru) 1999-08-16 2002-02-27 Пермское научно-производственное объединение "Биомед" Способ получения коллагеназы
EP1207840B1 (en) 1999-08-20 2004-10-13 Howard Murad Pharmaceutical compositions and methods for reducing the appearance of cellulite
US6280993B1 (en) * 1999-08-24 2001-08-28 Ichiro Yamato Gene encoding class I collagenase
ITMI991894A1 (it) 1999-09-09 2001-03-09 Carlo Ghisalberti Acido linoleico coniugato e trigliceride nuovi metodi di sintesi e d'uso
ES2534938T3 (es) 1999-09-24 2015-04-30 Proteon Therapeutics, Inc. Una elastasa para abrir conductos biológicos obstruidos
US7811250B1 (en) 2000-02-04 2010-10-12 Boston Scientific Scimed, Inc. Fluid injectable single operator exchange catheters and methods of use
US20030026844A1 (en) 2000-04-18 2003-02-06 Hee-Yong Lee Injectable sustained release pharmaceutical composition and processes for preparing the same
DK1356073T3 (da) 2000-10-20 2010-04-06 Bioneer As Fermenteringsfremgangsmåde til fremstilling af heterologe genprodukter i mælkesyrebakterier
DK1355566T3 (da) 2000-12-18 2013-03-04 Univ Texas Lokal regional kemoterapi og radioterapi ved anvendelse af hydrogel in situ
WO2002060410A2 (en) 2001-01-30 2002-08-08 The Regents Of The University Of Michigan Methods for sustained release local delivery of drugs for ablation of unwanted tissue
JP4266817B2 (ja) 2001-07-02 2009-05-20 ノルドマルク・アルツナイミッテル・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト 酵素の精製方法およびその方法で製造された精製済み酵素並びに該酵素の用途
GB0124124D0 (en) 2001-10-08 2001-11-28 Medical Res Council Methods of treatment
JP2003284553A (ja) 2002-03-28 2003-10-07 Seikagaku Kogyo Co Ltd 生理活性タンパク質
AU2002345319B2 (en) 2002-06-25 2008-03-06 Ultrashape Ltd. Devices and methodologies useful in body aesthetics
EP1433845A1 (en) * 2002-12-23 2004-06-30 Georg-August-Universität Clostridium tetani collagenase and uses thereof
EP1462519A1 (en) 2003-03-24 2004-09-29 Boehringer Ingelheim Austria GmbH Method and devices for producing biomolecules
JP4205496B2 (ja) 2003-06-19 2009-01-07 三菱化学株式会社 新規カルボニル還元酵素及びこれをコードするｄｎａ、ならびにこれらを利用した光学活性アルコールの製造方法
EP1709194A4 (en) 2003-12-17 2007-07-25 Univ Columbia DISTRIBUTION OF DNA OR RNA VIA NEXI OF HOST CELLS TO TARGET CELLS AND A CELL-BASED DELIVERY SYSTEM FOR ANTISENSE OR SIRNA
NZ589037A (en) 2004-01-30 2011-10-28 Shire Pharmaceuticals Ireland Ltd Production and purification of recombinant arylsulfatase A
SI1732949T1 (sl) 2004-04-07 2010-05-31 Rinat Neuroscience Corp Postopki za zdravljenje bolečine kostnega raka zdajanjem antagonista živčnega rastnega faktorja
US7754230B2 (en) 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
LT2422789T (lt) 2004-05-19 2018-03-12 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Injekcinės kompozicijos, apimančios natrio deoksicholiatą
US7355027B2 (en) 2004-06-16 2008-04-08 Dynport Vaccine Company Llc Bacillus anthracis protective antigen
EP1781697B1 (en) 2004-07-07 2009-04-22 H.Lundbeck A/S Novel carbamylated epo and method for its production
CA2572765C (en) 2004-07-08 2013-05-21 Amgen Inc. Compound having improved bioefficiency when administered in a multidose regimen
US20060020448A1 (en) 2004-07-21 2006-01-26 Microsoft Corporation Method and apparatus for capitalizing text using maximum entropy
WO2006025226A1 (ja) 2004-08-30 2006-03-09 Daicel Chemical Industries, Ltd. ポリグリセリンモノエーテル及びその製造方法
JP4923131B2 (ja) 2004-08-30 2012-04-25 株式会社リコー ログ収集システム、ログ収集装置およびログ収集プログラム
US20150025420A1 (en) 2004-10-06 2015-01-22 Guided Therapy Systems, Llc Ultrasound treatment device and methods of use
DE102004060075A1 (de) 2004-12-14 2006-07-06 Merck Patent Gmbh Verfahren zur Herstellung von Onium-Salzen mit Dialkylphosphat-, Dialkylphosphinat oder (O-Alkyl)-alkyl- oder Alkyl-phosphonat-Anionen mit geringem Halogenid-Gehalt
US7854929B2 (en) 2005-01-21 2010-12-21 The Research Foundation Of State University Of New York Method for treating lateral epicondylitis using collagenase
KR20090130158A (ko) 2005-01-21 2009-12-17 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 유착 관절낭염을 치료하는 방법
US20070224184A1 (en) 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
JP2006254876A (ja) 2005-03-18 2006-09-28 Hokkaido Univ Ｌ−トリプトファン製造法
US20060241673A1 (en) 2005-04-21 2006-10-26 Zadini Filiberto P Subcision device
US20060251581A1 (en) 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
US20070003541A1 (en) 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for therapeutics
ITPD20050207A1 (it) 2005-07-07 2007-01-08 Fidia Farmaceutici Nuove composizioni farmaceutiche contenenti acido ialuronico e collagenas nel trattamento topico di ferite, ustioni ed ulcere
US20070031482A1 (en) 2005-08-02 2007-02-08 Ceramoptec Industries, Ind. PDT treatment method for cellulites and cosmetic use
US7811560B2 (en) 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
WO2007100590A2 (en) 2006-02-22 2007-09-07 Auxilium Pharmaceuticals, Inc. Methods for treating cellulite
KR20090003281A (ko) 2006-03-31 2009-01-09 디에스엠 아이피 어셋츠 비.브이. 신체적 외관의 개선을 위한 화합물 및 화합물의 조합물의 신규한 용도
WO2008100833A2 (en) 2007-02-13 2008-08-21 Auxilium International Holdings, Inc. Production of recombinant collagenases colg and colh in escherichia coli
CN102784387A (zh) 2007-02-14 2012-11-21 友莱尔皮肤产品有限责任公司 修饰的突变体胶原蛋白酶及其在脂肪溶解和疤痕减少中的应用
AU2007353211B2 (en) 2007-05-11 2013-08-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Gel useful for the delivery of cosmetic active ingredients
US9987221B2 (en) 2007-08-23 2018-06-05 Boston Scientific Scimed, Inc. Injectable hydrogel compositions
JP5694772B2 (ja) 2007-10-26 2015-04-01 コーニンクレッカ フィリップス エヌ ヴェ 光角度選択型光検出装置
WO2009059379A1 (en) 2007-11-07 2009-05-14 Dynamic Microbials Limited Antimicrobial compositions, formulations and uses thereof
US20100159564A1 (en) * 2007-11-30 2010-06-24 Dwulet Francis E Protease resistant recombinant bacterial collagenases
EP2130551B1 (en) 2008-06-02 2012-06-06 Roche Diagnostics GmbH Improved purification of collagenases from clostridium histolyticum liquid culture
US8236356B2 (en) 2008-06-11 2012-08-07 Roche Diagnostics Operations, Inc. Growth medium for Clostridium histolyticum
CN102105133B (zh) 2008-07-21 2015-06-17 奥德纳米有限公司 控制释放型耳结构调节和先天性免疫系统调节组合物以及治疗耳部病症的方法
US8380531B2 (en) 2008-07-25 2013-02-19 Invivodata, Inc. Clinical trial endpoint development process
CA2741334A1 (en) 2008-10-22 2010-04-29 Allergan, Inc. Clinical assessment scales and methods
MX2011004666A (es) 2008-11-11 2011-05-31 Sigma Tau Ind Farmaceuti Compuesto util para tratar celulitis.
WO2010058707A1 (ja) * 2008-11-19 2010-05-27 明治製菓株式会社 アフィニティタグが結合した融合コラゲナーゼおよびその製造法
IT1397646B1 (it) * 2009-12-15 2013-01-18 Seidita Collagenasi ricombinanti di c. histolyticum e metodo per la loro produzione.
US9132199B2 (en) 2010-03-05 2015-09-15 University of Pittsburgh—of the Commonwealth System of Higher Education Reverse thermal gels and uses therefor
US20130195828A1 (en) 2010-04-14 2013-08-01 Northwestern University Pharmaceutical Compositions and Methods for Digesting Atherosclerotic Plaques
US20130217789A1 (en) 2010-09-03 2013-08-22 North Carolina Central University Biodegradable liquogel and ph sensitive nanocarriers
ES2385239B1 (es) * 2010-09-30 2013-06-19 Proteos Biotech S.L.U. Uso de colagenasa g recombinante, colagenasa h recombinante y pz-peptidasa recombinante para el tratamiento de enfermedades que cursan con alteraciones del colágeno.
US20120237492A1 (en) 2011-02-18 2012-09-20 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
WO2012125948A1 (en) 2011-03-16 2012-09-20 Biospecifics Technologies Corp. Compositions and methods for producing clostridial collagenases
TWI461214B (zh) 2011-06-13 2014-11-21 Univ Chang Gung Biodegradable water-sensitive glue, a drug delivery system as a carrier thereof, and a pharmaceutical composition for the treatment and / or prevention of eye diseases
EP2768414B1 (en) 2011-10-17 2018-09-26 Sound Surgical Technologies LLC Ultrasonic probe for treating cellulite
ES2741476T3 (es) 2011-10-21 2020-02-11 Endo Global Ventures Método para el tratamiento o reducción de PFE
AU2013208028B2 (en) 2012-01-12 2016-04-28 Auxilium International Holdings, Inc. Clostridium histolyticum enzymes and methods for the use thereof
JP6049862B2 (ja) 2012-09-07 2016-12-21 株式会社 資生堂 フィブリン３及び／又はサルコグリカンγを指標としたセルライトの評価方法及びセルライト効果薬剤の評価方法
US20160000890A1 (en) 2013-03-15 2016-01-07 Biospecifics Technologies Corp. Thermosensitive hydrogel collagenase formulations
EP2968484B1 (en) 2013-03-15 2020-11-25 BioSpecifics Technologies Corporation Treatment method and product for uterine fibroids using purified collagenase
US9463155B2 (en) 2013-03-15 2016-10-11 Mary Kay Inc. Cosmetic compositions and uses thereof
CN103751102A (zh) 2014-01-15 2014-04-30 上海交通大学 一种胶原酶温敏水凝胶及其制备方法和应用
US10729700B2 (en) 2014-06-27 2020-08-04 Medytox Inc. Methods and compositions of bile acids and salts for reduction of fat
AU2017218522A1 (en) 2016-02-08 2018-08-23 OutcomeMD, Inc. Determining a wellness, improvement, or effectiveness score
WO2018077825A1 (en) 2016-10-28 2018-05-03 Merz Pharma Gmbh & Co. Kgaa Treatment of gynoid lipodystrophy
CN115969318A (zh) 2017-03-01 2023-04-18 恩多风投有限公司 用于评估和治疗橘皮组织的装置和方法
EP3601556A2 (en) 2017-03-28 2020-02-05 Endo Ventures Limited Improved method of producing collagenase

Also Published As

Publication number Publication date
NZ718173A (en) 2017-09-29
CA2970639A1 (en) 2013-07-18
BR112014017229A8 (pt) 2017-07-04
JP2022023041A (ja) 2022-02-07
NZ766918A (en) 2023-03-31
US20250222080A1 (en) 2025-07-10
WO2013106510A2 (en) 2013-07-18
JP2019103505A (ja) 2019-06-27
JP2020188810A (ja) 2020-11-26
US20250041391A1 (en) 2025-02-06
ES2740499T3 (es) 2020-02-05
BR112014017229B1 (pt) 2022-05-17
US10603365B2 (en) 2020-03-31
ES2968836T3 (es) 2024-05-14
DK2802652T3 (da) 2019-07-15
AU2019200192B2 (en) 2021-07-01
AU2023229488B2 (en) 2025-11-27
AU2016208378A1 (en) 2016-08-18
US12263209B2 (en) 2025-04-01
EP4276180A3 (en) 2024-01-10
EP2802652A2 (en) 2014-11-19
US9757435B2 (en) 2017-09-12
EP2802652B1 (en) 2019-06-05
AU2016208384C1 (en) 2023-10-05
AU2016208384A1 (en) 2016-08-11
CA2861033C (en) 2017-07-25
NZ627372A (en) 2016-04-29
EP3584317B1 (en) 2021-11-24
JP6947888B2 (ja) 2021-10-13
US11975054B2 (en) 2024-05-07
EP2802652A4 (en) 2015-10-14
HUE057423T2 (hu) 2022-05-28
PT3584317T (pt) 2022-01-26
ES2904884T3 (es) 2022-04-06
AU2013208028B2 (en) 2016-04-28
US20180055918A1 (en) 2018-03-01
NZ750379A (en) 2022-10-28
DK3584317T5 (da) 2022-01-17
CA2861033A1 (en) 2013-07-18
JP2015506176A (ja) 2015-03-02
HUE046160T2 (hu) 2020-02-28
NZ733709A (en) 2022-10-28
AU2019200192A1 (en) 2019-04-04
WO2013106510A3 (en) 2013-10-03
EP4015627B1 (en) 2023-09-27
DK3584317T3 (en) 2022-01-03
US11879141B2 (en) 2024-01-23
JP2018075011A (ja) 2018-05-17
US20240269245A1 (en) 2024-08-15
CA2970639C (en) 2022-04-26
AU2021221653A1 (en) 2021-09-23
PT2802652T (pt) 2019-09-10
US20200206326A1 (en) 2020-07-02
US20150010532A1 (en) 2015-01-08
AU2016208384B2 (en) 2018-09-13
US20230416717A1 (en) 2023-12-28
EP3584317A1 (en) 2019-12-25
MX351448B (es) 2017-10-16
JP7354197B2 (ja) 2023-10-02
BR112014017229A2 (pt) 2017-06-13
EP4276180A2 (en) 2023-11-15
MX387336B (es) 2025-03-18
AU2023229488A1 (en) 2023-09-28
JP6496386B2 (ja) 2019-04-03
NZ797997A (en) 2024-05-31
JP6752309B2 (ja) 2020-09-09
US20240252602A1 (en) 2024-08-01
AU2021221653B2 (en) 2023-10-05
JP6263755B2 (ja) 2018-01-24
EP4015627A1 (en) 2022-06-22
AU2013208028A1 (en) 2014-08-07
AU2016208378B2 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
MX2014008441A (es) Enzimas de clostridium histolyticum y metodos para el uso de los mismos.
AR118777A2 (es) Neurotoxinas catiónicas
AU2011372711B2 (en) Method for processing mesenchymal stem cells and the use thereof in the treatment of diseases associated with oxidative stress
MX359449B (es) Conjugados de anticuerpo fármaco anti-cd70.
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
BR112018004377A2 (pt) cepas de levedura para a expressão e secreção de proteínas heterólogas em temperaturas elevadas
SA520412669B1 (ar) تصنيع ذيفانات عصبية ناتجة عن معاودة الارتباط الجيني من المطثية الوشيقية
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
BR112013004124A2 (pt) peptídeo ou complexo de peptídeos ligando a alfa2 integrina e métodos e utilizações envolvendo os mesmos
BR112015004467A2 (pt) método para controlar a heterogeneidade de proteínas
MX348188B (es) Composiciones y metodos para pruebas de toxigenicidad.
MX349947B (es) Metodos de tratamiento de inflamacion neurogenica cronica usando una toxina clostridial modificada.
ES2721930T3 (es) Composición inmunogénica
MX2019009222A (es) Neurotoxinas recombinantes de clostridium botulinum.
WO2012096926A3 (en) Method for delivering agents into cells using bacterial toxins
BR112014024282A2 (pt) anticorpos ligantes ao receptor b1 da bradicinina
MX2016003737A (es) Microorganismo recombinante para la mejora de produccion de productos quimicos finos.
AR090668A1 (es) Anticuerpo anti-adamts-5, derivados y usos del mismo
MY193287A (en) Recombinant microorganism for improved production of fine chemicals
GB2497453A (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
NZ725212A (en) Group a streptococcus vaccine
BR112015009287A2 (pt) biocontrole de nematódeos
WO2012166848A3 (en) Methods and compositions for the detection of functional clostridium difficile toxins
BR112013004743A2 (pt) polipeptídeo isolado com atividade de endopeptidase, composição, método para produzir o polipeptídeo, preparar um hidrolisado de proteína, e para preparar um hidrolisado de proteína alimentar, e, usos do polipeptídeo ou da composição, e de uma endopeptidase do tipo tripsina derivada de uma bactéria
IN2013MU02316A (es)

Legal Events

Date Code Title Description
FG Grant or registration